StockNews.AI
ADGM
StockNews.AI
141 days

Adagio Medical Reports Fourth Quarter and Full Year 2024 Results

1. Adagio Medical reported Q4 2024 revenue of $137K, up from $78K in 2023. 2. Full-year 2024 revenue increased to $0.6M, doubling 2023's $0.3M.

Earnings
-12.49%Current Return
VS
+0.64%S&P 500
$0.939903/31 08:42 AM EDTEvent Start
$0.822504/01 03:35 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The revenue growth shows a positive trend, indicating a strengthening market position, reminiscent of biotech firms' rise post-product approval.

How important is it?

Strong revenue growth can attract investors, influencing ADGM’s market perception and stock price.

Why Short Term?

Short-term stock reactions are often driven by quarterly results; positive revenue growth may spark immediate investor interest.

Related Companies

ADGM
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights: Reported total company revenue of $137 thousand in the fourth quarter of 2024, compared to $78 thousand in the fourth quarter of 2023. Full year revenue for 2024 was $0.6 million compared to $0.3.

Related News